UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 10-QSB



QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934





FOR THE PERIOD ENDED: December 31, 2002

COMMISSION FILE NUMBER: 333-06718



VIROPRO INC.

------------------------------------------------------

(Exact name of registrant as specified in its charter)





NEVADA                                            13-3124057

-------------------------------                         --------------------

(State or other jurisdiction of                         (IRS Employer

incorporation or organization)                           Identification No.)



3163 Kennedy Boulevard, Jersey City, New Jersey 07306

------------------------------------------------------------

(Address, including zip code, of principal executive offices)



(201) 217-4137

---------------------------------------------------

(Registrant's telephone number, including area code)



N/A

------------------------------------------------------------------------

(Former name, former address & former fiscal year, if changed since last report)



Indicate by check  mark whether the  registrant (1) has filed all  documents and

reports required to be filed by Sections 13 or 15(d) of  the Securities Exchange

Act of 1934 during the preceding  12 months (or for such shorter period that the

registrant was required to  file such reports), and (2) has been subject to such

filings for the past 90 days.



YES  (X)    NO  ()



APPLICABLE ONLY TO CORPORATE ISSUERS:



As of December 31, 2002, the number of the Company's shares of par value $.001

common stock outstanding was 7,324,749.





















---

VIROPRO, INC.

FORM 10-QSB

DECEMBER 31, 2002





INDEX





Condensed Consolidated Balance Sheet..........................................3



Consolidated Statements of Operation..........................................4



Consolidated Statements of Cash Flow..........................................5



Notes to Financial Statements.................................................6





Item 2 - Management's Discussion and Analysis of Financial Condition and

Results of Operations............................................ 8





PART II - OTHER INFORMATION.................................................. 9





SIGNATURES................................................................... 9



























































---

VIROPRO, INC.

FORM 10-QSB

DECEMBER 31, 2002



Part I - FINANCIAL INFORMATION



Item 1 - Financial Statements



|VIROPRO, INC.
CONSOLIDATED BALANCE SHEET
(UNAUDITED)
|----------------------------------------------------

| |  | 
| |  | 

|Assets | 
|------ | 

| |  |                  
| |  | -----------------
| |  | December 31, 2002
| |  |                  
| |  |                  

|Current Assets | -
|-------------- | -

| |                      |            
| | -------------------- | -----------
| |                      |            
| | Total current assets | -          
| |                      |            
| |                      |            
| |                      |            
| | Total assets         | $         -
| |                      |            
| |                      |            
| |                      |            
| |                      |            

|Liabilities and Shareholder's Equity | 
|------------------------------------ | 

| |  | 
| |  | 

|Current Liabilities | 
|------------------- | 

| |                                  |        
| | -------------------------------- | -------
| | Accrued interest - related party | 268,166
| | Notes payable - related party    | 583,200
| |                                  |        
| | Total current liabilities        | 851,366
| |                                  |        
| |                                  |        

|Shareholder's Equity | 
|-------------------- | 

| | Common Stock, $.001 par value; authorized           | 7,475       
| | --------------------------------------------------- | ------------
| | 50,000,000 shares; issued and outstanding 7,474,749 |             
| | Paid in Capital                                     | 1,102,584   
| | Accumulated Deficit                                 | (1,961,425) 
| |                                                     |             
| | Total Shareholder's Equity/(Deficit)                | (851,366)   
| |                                                     |             
| | Total liabilities and shareholder's equity          | $          -
| |                                                     |             
| |                                                     |             
| |                                                     |             





Read the accompanying significant accounting notes to financial statements, which are an integral part of this financial statement.



---



|VIROPRO, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2002 AND 2001
|----------------------------------------------------------------------------------------------------------------

| |  |  |  | 
| |  |  |  | 

| | Three months ended |  | Six months ended
| | ------------------ |  | ----------------

|                                                         | December 31, 2002 |  | December 31, 2001 |  | December 31, 2002 |  | December 31, 2001
|-------------------------------------------------------- | ----------------- |  | ----------------- |  | ----------------- |  | -----------------
|                                                         | (Unaudited)       |  | (Unaudited)       |  | (Unaudited)       |  | (Unaudited)      
|                                                         |                   |  |                   |  |                   |  |                  
|Revenue                                                  | $         -       |  | $          -      |  | $         -       |  | $         -      
|                                                         |                   |  |                   |  |                   |  |                  
|Cost of Revenue                                          | -                 |  | -                 |  | -                 |  | -                
|                                                         |                   |  |                   |  |                   |  |                  
|Gross Profit                                             | -                 |  | -                 |  | -                 |  | -                
|                                                         |                   |  |                   |  |                   |  |                  
|Operating expenses:                                      |                   |  |                   |  |                   |  |                  
|Selling, general and administrative expenses             | -                 |  | -                 |  | -                 |  | -                
|Total operating expenses                                 | -                 |  | -                 |  | -                 |  | -                
|                                                         |                   |  |                   |  |                   |  |                  
|Income(Loss) before other income (expense)               | -                 |  | -                 |  | -                 |  | -                
|                                                         |                   |  |                   |  |                   |  |                  
|Other income (expense):                                  |                   |  |                   |  |                   |  |                  
|Interest expense (principally related party)             | (14,580)          |  | (14,580)          |  | (29,160)          |  | (29,160)         
|Total other income (expense)                             | (14,580)          |  | (14,580)          |  | (29,160)          |  | (29,160)         
|                                                         |                   |  |                   |  |                   |  |                  
|Income (Loss) from continuing operations                 | (14,580)          |  | (14,580)          |  | (29,160)          |  | (29,160)         
|                                                         |                   |  |                   |  |                   |  |                  
|Discontinued operations:                                 |                   |  |                   |  |                   |  |                  
|Gain on assignment of subsidiary                         | 210,125           |  | -                 |  | 210,125           |  | -                
|Income (Loss) from operations of discontinued subsidiary | -                 |  | -                 |  | -                 |  | -                
|                                                         | 210,125           |  | -                 |  | 210,125           |  | -                
|                                                         |                   |  |                   |  |                   |  |                  
|                                                         |                   |  |                   |  |                   |  |                  
|Net Income (Loss)                                        | $   195,545       |  | $   (14,580)      |  | $   180,965       |  | $   (29,160)     
|                                                         |                   |  |                   |  |                   |  |                  
|Basic weighted average common shares outstanding         | 7,474,749         |  | 7,474,749         |  | 7,474,749         |  | 7,474,749        
|                                                         |                   |  |                   |  |                   |  |                  
|Basic and diluted Loss per common share                  | $0.03             |  | $(0.00)           |  | $0.02             |  | $(0.00)          
|                                                         |                   |  |                   |  |                   |  |                  















Read the accompanying significant accounting notes to financial statements, which are an integral part of this financial statement.





---



|VIROPRO, INC.
STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED DECEMBER 31, 2002 AND 2001
|-----------------------------------------------------------------------------------------

| |  | Six months ended
| |  | ----------------

| |  | December 31, 2002 |  | December 31, 2001
| |  | ----------------- |  | -----------------
| |  | (Unaudited)       |  | (Unaudited)      
| |  |                   |  |                  

|CASH FLOWS FROM OPERATING ACTIVITIES: |  |  | 
|------------------------------------- |  |  | 

| |  |  |  | 
| |  |  |  | 

|Net Income (Loss) | $   180,965 |  | $   (29,160)
|----------------- | ----------- |  | ------------

| |  |  |  | 
| |  |  |  | 

|Changes in Operating assets and liabilities: |           |  |       
|-------------------------------------------- | --------- |  | ------
|Accounts Payable and Accrued Liabilities     | (180,965) |  | 29,160

| |  |  |  | 
| |  |  |  | 

|Net cash provided by/(used in) operating activities | - |  | -
|--------------------------------------------------- | - |  | -

| |  |  |  | 
| |  |  |  | 
| |  |  |  | 

|CASH FLOWS FROM INVESTING ACTIVITIES: |  |  | 
|------------------------------------- |  |  | 

| |  |  |  | 
| |  |  |  | 
| |  |  |  | 

|Net cash provided by/(used in) investing activities | - |  | -
|--------------------------------------------------- | - |  | -

| |  |  |  | 
| |  |  |  | 
| |  |  |  | 

|CASH FLOWS FROM FINANCING ACTIVITIES: |  |  | 
|------------------------------------- |  |  | 

| |  |  |  | 
| |  |  |  | 
| |  |  |  | 

|Net cash provided by/(used in) financing activities | - |  | -
|--------------------------------------------------- | - |  | -

| |  |  |  | 
| |  |  |  | 
| |  |  |  | 

|Net increase (decrease) in cash and cash equivalents | - |  | -
|---------------------------------------------------- | - |  | -
|Cash and cash equivalents, beginning of period       | - |  | -

| |  |  |  | 
| |  |  |  | 

|Cash and cash equivalents, end of period | $         - |  | $          -
|---------------------------------------- | ----------- |  | ------------

| |  |  |  | 
| |  |  |  | 
| |  |  |  | 

|Supplemental information: |  |  | 
|------------------------- |  |  | 

|     |  |  |  | 
|---- |  |  |  | 
|None |  |  |  | 
|     |  |  |  | 
|     |  |  |  | 
|     |  |  |  | 
|     |  |  |  | 











Read the accompanying significant accounting notes to financial statements, which are an integral part of this financial statement.





---

VIROPRO, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)



NOTE 1 –BASIS OF PRESENTATION



The accompanying unaudited consolidated financial statements of Viropro, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Article 10 of Regulation S-X.  The financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the results for the periods shown.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.



These financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in Viropro Inc.’s form 10-KSB as filed with the Securities and Exchange Commission.



The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and that effect the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.



NOTE 2 – NET EARNINGS/(LOSS) PER SHARE



Earnings (Loss) per common share are calculated under the provisions of SFAS No. 128, “Earnings per Share,” which establishes standards for computing and presenting earnings per share.  SFAS No. 128 requires the Company to report both basic earnings (loss) per share, which is based on the weighted-average number of common shares outstanding during the period, and diluted earnings (loss) per share, which is based on the weighted-average number of common shares outstanding plus all potential dilutive common shares outstanding.  Options and warrants are not considered in calculating diluted earnings (loss) per share since considering such items would have an anti-dilutive effect.



NOTE 3 – GOING CONCERN



The accompanying financial statements have been prepared assuming the Company will continue as a going concern.  The company reported a net loss of $29,160 (unaudited) from continuing operations for the six months ended December 31, 2002. Continuation of the Company as a going  concern is  dependent  upon  obtaining sufficient  working  capital for its planned activity.  Additional capital and/or borrowings will be necessary in order for the Company to continue in existence until attaining and sustaining profitable operations.  The Company is aggressively pursuing strategic alliances which will bring a cash infusion, restructuring and a forward looking business plan.



NOTE 4 -RELATED PARTY TRANSACTIONS



Between September 1997 through June 1999, the Company borrowed funds under notes payable aggregating $583,200 from Jade Investments, as major shareholder controlled entity, with interest at 10%. The notes are payable on demand. Interest of $268,166 has been accrued at December 30, 2002. No payments have been made.







---

VIROPRO, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)



NOTE 5 – ASSIGNMENT OF WHOLLY-OWNED SUBSIDIARY



On October 16, 2002, the Company assigned all of its rights, title and interest of its wholly-owned subsidiary Insecta Sales & Research, Inc. to Prime Time Insects, Inc. (A Bahamian Corporation) owned by a related party. In consideration for these assets and the use of the "Insecta" name and abandoned EPA registration, "Prime Time" will assume in its entirety an accounts payable of $210,125 of Insecta Sales & Research, Inc.































































































---

VIROPRO, INC.

FORM 10-QSB

DECEMBER 31, 2002



ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.





RESULTS OF OPERATIONS THREE AND SIX MONTHS ENDED DECEMBER 31, 2002 AND 2001.



During the three month period ending December 31, 2002 the Company’s net income was 195,545 compared to a loss of $14,580 for the same period in the prior year.   The change from year to year was related to a one-time gain realized from the assignment of its wholly-owned subsidiary whereby, the assignee assumed accounts payable in the amount of $210,125.   Gross profit for the three-month periods ended December 31, 2002 and 2001 was zero dollars. The Company incurred no operating expenses during the three-month periods ended December 31, 2002 and 2001.



During the six month period ending December 31, 2002 the Company’s net income was 180,965 compared to a loss of $29,160 for the same period in the prior year.   The change from year to year was related to a one-time gain realized from the assignment of its wholly-owned subsidiary whereby, the assignee assumed accounts payable in the amount of $210,125.   Gross profit for the six-month periods ended December 31, 2002 and 2001 was zero dollars. The Company incurred no operating expenses during the six-month periods ended December 31, 2002 and 2001.



REVENUES



During the three and six month periods ended December 31 2002 and 2001, the Company's revenues were zero dollars. Revenues were previously derived from the sale of the insecticide products sold under the Insecta Brand name. Revenues were recognized when the product sold was shipped to the Company's customer. The absence of revenue from year to year is due to the Company ceasing its business operations due to the EPA changing the applicable regulations covering the sale and distribution of products containing the active ingredient in the Company's Insecta brand insecticide. As previously reported the Company was notified that effective December 2001 the active ingredient of its insecticide formulation could no longer be sold.



OPERATING EXPENSES



During the three and six months ended December 31, 2002 and 2001 the Company incurred no operating expenses. This reflects the above-mentioned cessation of business due to changes in EPA regulations.



MATERIAL CHANGES IN FINANCIAL CONDITION, LONGEVITY AND CAPITAL RESOURCES.



At December 31, 2002, the Company had $0 in cash and cash equivalents, the same as at the start of the fiscal year, June 30, 2002.























---

VIROPRO, INC.

FORM 10-QSB

DECEMBER 31, 2002





PART  II



OTHER  INFORMATION



Item  1.  Legal  Proceedings.



NONE



Item  2.  Changes  in  Securities.



NONE



Item 3.  Defaults  Upon  Senior  Securities.



None.



Item  4.  Submission  of  Matters  to  a  Vote  of  Security-Holders.



None



Item  5.  Other  Information.



NONE





Item  6.  Exhibits  and  Reports  on  Form  8-K.



(a)      Omitted exhibits not required.



(b)      Reports  on  Form  8-K



No reports on Form 8-K were filed in the period ending December 31, 2002.







SIGNATURE



In  accordance  with  the requirements of the Security Exchange Act of 1934, the

Registrant has caused this report to be signed on its behalf by the undersigned,

duly  authorized.



VIROPRO, INC.





Date: February 19, 2002                 By: /s/ Hugh Johnson

--------------------------------

Hugh Johnson, President









---



CERTIFICATION OF CHIEF EXECUTIVE OFFICER



I, Hugh Johnson, certify that:



1.

I have reviewed this revised quarterly report on Form 10-QSB of VIROPRO, INC.;



2.

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;



3.

Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present, in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;



4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:



a)

designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b)

evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and



c)

presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;



5.

I have disclosed, based on my most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):



a)

all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and



6.

I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.





Date: February 19, 2002                 By: /s/ Hugh Johnson

--------------------------------

Hugh Johnson, President